[company_age]17.0[/company_age][employees]51-100 employees[/employees][funding]post_ipo_equity[/funding][description]BioAtla, a San Diego-based biopharmaceutical company, is revolutionizing cancer treatment with its innovative approach. Their proprietary Conditionally Active Biologics™ (CAB) platform leverages the unique microenvironment of diseased tissue to precisely target cancer cells, minimizing side effects and maximizing therapeutic efficacy. This technology sets BioAtla apart from its competitors, who often struggle with the limitations of traditional cancer therapies. BioAtla's commitment to integrity is evident in their comprehensive training programs covering safety, ethics, and data protection. They actively engage with their community through summer internship programs and prioritize employee development, fostering a diverse and inclusive workplace. BioAtla's leadership team comprises experienced professionals with a proven track record of success, further solidifying their position as a leader in the field of cancer treatment.[/description][ps]Conditionally Active Biologics™ (CAB) platform for developing safer and more effective cancer treatments.[/ps]